Recently, Johnson & Johnson's pharmaceutical subsidiary Xi'an Yangsen Pharmaceutical Co., Ltd. signed a strategic cooperation agreement with Ali Health to explore a "patient-centered" Internet medical health service model.
"Through the Internet, we will provide online medical and health services such as drug knowledge inquiry, disease consultation, and outpatient appointments. In addition, different forms of cooperation will be carried out in medical e-commerce, drug traceability and smart medical care. More patients can enjoy the health management lifestyle of the 'Internet + medical' era without leaving home, improve the efficiency of communication between doctors and patients, reduce operating costs, and achieve optimal allocation of medical public resources." Xi'an Janssen Pharmaceutical Co., Ltd. President Ansgar (Asgar) Rangoonwala) told the Science and Technology Daily reporter.
Ansgar said: "At present, the scope of the Internet services provided by both parties includes tumors, immune diseases and pulmonary hypertension. This long-term cooperation will bring health services to more than 15 million Chinese patients, and will gradually cover in the future. To the dermatology, anti-allergy and infectious disease vaccines."
In 1985, Xi'an Janssen entered China for the first time. In 2018 alone, Xi'an Janssen has been approved for 11 new products and indications in China. So far, 44 drugs have been included in the China National Health Insurance Catalog.
“The drugs we have approved are all characterized by breakthrough innovation. Benefiting from the acceleration of the Chinese government's process of approval of innovative drugs, we hope to bring a full lineup of innovative products to China in the future. The reason why Johnson & Johnson succeeded was because many years ago Breakthrough innovation is used as a strategy in various fields, including cancer, immunity, and mental illness. For example, in the fields of schizophrenia, diabetes, and immunity, we have introduced innovative products that can save lives and are our level of innovation. Representative," said Ansca.
An Sijia said that in 2019, Xi'an Janssen will do more market penetration and accessibility for the 11 new products and indications approved this year.
Stereo Microscope ,Stereoscopic Microscope,Stereo Zoom Microscope,Stereoscopic Binocular Microscope
Ningbo ProWay Optics & Electronics Co., Ltd. , https://www.proway-microtech.com